Pain company Centrexion proposes NASDAQ IPO

Pain company Centrexion Therapeutics Corp. (Boston, Mass.) proposed to raise up to $86.3 million in an IPO on NASDAQ. BofA Merrill Lynch, Leerink and Evercore ISI are underwriters.

Centrexion expects top-line results from the Phase III VICTORY-1 trial in 2020. The trial is evaluating lead candidate CNTX-4975 to treat moderate to severe chronic pain associated with osteoarthritis of the knee. The biotech anticipates top-line data from a safety trial in 2H19 and from the Phase III VICTORY-2 trial in 2H20...